Pulmovant is a clinical-stage biotechnology company developing innovative therapies for patients suffering from pulmonary diseases. Pulmovant’s first program, mosliciguat is designed to provide an effective, once-daily, inhaled treatment option for patients with pulmonary hypertension (PH). Mosliciguat is a novel, potential first-in-class, sGC activator with a differentiated mechanism that may have broad applicability across the PH spectrum.

Biotechnology

Clinical Trials

Health Care

Therapeutics

Pulmovant

Pulmovant's headquarters in Waltham, United States

Description

People (3)

Bill Gerhart

Sabina Waid

Allison W.

Jobs